Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARISTADA vs ABILIFY MAINTENA KIT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Schizophrenia,Maintenance monotherapy of bipolar I disorder in adults
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
Terminal elimination half-life of aripiprazole lauroxil (the prodrug in ARISTADA) is approximately 54 days (range 29-74 days) after IM injection, allowing monthly dosing.
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Aripiprazole lauroxil is hydrolyzed by esterases to N-hydroxymethyl aripiprazole, which is then converted to aripiprazole. Aripiprazole is primarily metabolized by CYP2D6 and CYP3A4.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Primarily renally excreted (approximately 60% as metabolites, <1% unchanged). Fecal elimination accounts for about 20%.
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
>99% bound, primarily to albumin.
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
Approximately 4.9 L/kg (based on aripiprazole), indicating extensive tissue distribution.
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Intramuscular: 100% (complete release from injection site). Oral aripiprazole: 87%.
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to limited data.
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
No dosage adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended for moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of studies.
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
Safety and efficacy not established in pediatric patients under 18 years of age.
Not approved for pediatric use.
No specific dosage adjustment recommended, but caution due to potential increased sensitivity and renal function decline. Monitor for adverse effects and consider lower initial doses if clinically appropriate.
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ARISTADA is not approved for the treatment of patients with dementia-related psychosis.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events in elderly patients with dementia,Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes (hyperglycemia, dyslipidemia, weight gain),Orthostatic hypotension,Leukopenia, neutropenia, and agranulocytosis,Seizures,Body temperature dysregulation,Dysphagia,Potential for cognitive and motor impairment
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Hypersensitivity to aripiprazole or any component of the formulation
Hypersensitivity to aripiprazole or any excipients in the formulation.
Avoid grapefruit juice due to CYP3A4 inhibition. No specific food restrictions beyond that.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
Aristada (aripiprazole lauroxil) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, aripiprazole caused developmental toxicity, including teratogenic effects, at doses similar to or less than the maximum recommended human dose (MRHD). During the first trimester, there is a potential risk of major congenital malformations, although data are limited. During the second and third trimesters, exposure may increase the risk of extrapyramidal symptoms and/or withdrawal symptoms in neonates, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder.
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
Aripiprazole is excreted in human breast milk; the milk-to-plasma ratio (M/P) is approximately 0.5 to 3.0 based on limited data. In lactating women, the relative infant dose (RID) is estimated to be about 1.4% to 8.3% of the weight-adjusted maternal dose. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for Aristada and any potential adverse effects on the breastfed child. Monitor the infant for signs of sedation, extrapyramidal symptoms, or inadequate weight gain.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) may reduce aripiprazole levels. Although no specific dose adjustment guidelines are established for Aristada, therapeutic drug monitoring of aripiprazole and its active metabolite dehydroaripiprazole may be considered to maintain efficacy. Dose adjustments should be individualized based on clinical response and tolerability, with careful monitoring during pregnancy and postpartum.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
Initiate with a single 672 mg test dose to confirm tolerability. Administer only via gluteal IM injection; do not administer IV. The drug forms a liquid crystal depot upon injection. Ensure proper needle selection: 2-inch needle for gluteal injection. Do not massage injection site. Monitor for post-injection syndrome (rare but serious).
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
Do not stop taking this medication abruptly; continue regular visits for injections.,Report any severe muscle stiffness, fever, confusion, or irregular heartbeat immediately.,Avoid alcohol and grapefruit juice while on this medication.,You may experience injection site reactions; notify your doctor if they worsen.,Use effective contraception if of childbearing potential; discuss risks with your doctor.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARISTADA vs ABILIFY MAINTENA KIT, answered by our medical review team.
ARISTADA is a Atypical Antipsychotic that works by Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.. ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARISTADA and ABILIFY MAINTENA KIT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARISTADA is: Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.. The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARISTADA and ABILIFY MAINTENA KIT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARISTADA is classified as Category C. Aristada (aripiprazole lauroxil) is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, aripipr. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.